Process Development

Home > R&D > Research Protfolio > Process Development

The process development research group performs research for the rapid commercialization of anti-cancer, anti-diabetes, and anti-viral agents. We do this by developing new synthesis methods, such as complex synthetic processes and chirotechnologies.

  • 2008's

    Launched and mass produce Orlistat (Lipidown), anti-obesity agents

  • 2007's

    Developed a new synthetic method for Montelukast, the anti-asthma agent

  • 1997's

    Developed a new synthetic method for Capecitabine, the anti-cancer drug

  • 1989's

    launched Gemcitabine (Gembin)

  • 1989's

    Developed synthetic methods for Gemcitabine, the anti-cancer drug, and Voglibose, the anti-diabetes

  • 1989's

    Developed a synthetic process for Cefpodoxime proxetil, 3rd generation oral cephalosporin antibiotics

  • 1989's

    Developed a synthetic process for Clarithromycin, the 3rd generation antibiotic

  • 1989's

    Developed a synthetic method for Cefixime, the 3rd generation oral antibiotic

  • 1989's

    Developed a synthetic method for Ceftazidime pentahydrate, the 3rd generation injectable antibiotic

    Developed a synthetic method for Cefotiam hydrochloride, the 2nd generation injectable cephalosporin

  • 1989's

    Transferred synthetic technology of 3rd generation cephalosporin, Ceftriaxone, to Hoffman-La Roche

  • 1989's

    Developed a synthetic process for Ceftriaxone, the 3rd generation and once daily
    injectable cephalosporin

  • 1989's

    Developed a new synthetic method for Cefotaxime, the 3rd generation cephalosporin antibiotic